Alpha 2.0
Login Register
» Authors » Maryam Taghdiri

Maryam Taghdiri

Explore the profile of Maryam Taghdiri including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 236
Followers 0
Related Specialties
Pediatrics
Biochemistry
Molecular Biology
Top 10 Co-Authors
Seyed Reza Banihashemi
Ali Es-Haghi
Mohammad Hossein Fallah Mehrabadi
Kimia Kahrizi
Hossein Najmabadi
Ali Rezaei Mokarram
Vahideh Mohseni
Saeed Kalantari
Fariba Sadeghi
Majid Fardaei
Published In
Clin Case Rep
Int J Pediatr Otorhinolaryngol
Vaccines (Basel)
Sci Rep
Eur J Pediatr
Affiliations
Soon will be listed here.
Recent Articles
1.
Comprehensive copy number analysis of spinal muscular atrophy among the Iranian population
Khanbazi A, Beheshtian M, Azad M, Akbari Kelishomi M, Afroozan F, Fatehi F, et al.
Sci Rep . 2024 Dec; 14(1):29880. PMID: 39622884
Copy number variations in the SMN1 gene on chromosome 5 are the primary cause of Spinal Muscular Atrophy (SMA) disease, characterized by muscle weakness and degeneration due to impaired alpha...
2.
Safety and Immunogenicity of Intranasal Razi Cov Pars as a COVID-19 Booster Vaccine in Adults: Promising Results from a Groundbreaking Clinical Trial
Fallah Mehrabadi M, Hajimoradi M, Es-Haghi A, Kalantari S, Noofeli M, Mokarram A, et al.
Vaccines (Basel) . 2024 Nov; 12(11). PMID: 39591158
Protective antibodies in the upper respiratory tract prevent the spread of COVID-19 in the community. Intranasal vaccines could raise the specific secretory IgA and IgG levels. This is a single-center,...
3.
Characterization of Luciferase from and its Application for Imaging Studies in Mice
Tarahomjoo S, Ebrahimi L, Valishahavaz F, Taghdiri M, Banihashemi R
Protein Pept Lett . 2024 Oct; 31(10):806-817. PMID: 39444186
Background: Bioluminescence, or the production of light by luciferases, is the basis of a well-known reporter technology. A quick way to study the efficacy of antimicrobial drugs and vaccines is...
4.
Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets
Taghdiri M, Mussolino C
Int J Mol Sci . 2024 Jul; 25(13). PMID: 39000440
Clustered regularly interspersed short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology has revolutionized the field of gene therapy as it has enabled precise genome editing with unprecedented accuracy and efficiency,...
5.
Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: A phase III, non-inferiority trial
Solaymani-Dodaran M, Kalantari S, Banihashemi S, Es-Haghi A, Nofeli M, Mohazzab A, et al.
Heliyon . 2024 Mar; 10(5):e27370. PMID: 38463808
Background: We conducted a phase III, non-inferiority trial comparing safety and efficacy of RCP recombinant spike protein Covid-19 vaccine to BBIBP (Sinopharm). Methods: Adult Iranian population received RCP or BBIBP...
6.
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial
Erfanpoor S, Banihashemi S, Mokhbaeralsafa L, Kalantari S, Es-Haghi A, Nofeli M, et al.
BMC Med . 2024 Feb; 22(1):78. PMID: 38378570
Background: The immunity induced by primary vaccination is effective against COVID-19; however, booster vaccines are needed to maintain vaccine-induced immunity and improve protection against emerging variants. Heterologous boosting is believed...
7.
Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18-70 Years; A Randomized, Double-Blind Clinical Trial
Mohazzab A, Fallah Mehrabadi M, Es-Haghi A, Kalantari S, Mokhberalsafa L, Setarehdan S, et al.
J Pharm Sci . 2023 Oct; 112(12):3012-3021. PMID: 37832918
Background: This study explores the safety and immunogenicity of the Razi-Cov-Pars (RCP) SARS Cov-2 recombinant spike protein vaccine. Method: In a randomized, double-blind, placebo-controlled trial, adults aged 18-70 were randomly...
8.
Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial
Dodaran M, Banihashemi S, Es-Haghi A, Fallah Mehrabadi M, Nofeli M, Mokarram A, et al.
Vaccines (Basel) . 2023 Feb; 11(2). PMID: 36851334
: This study aimed to determine the safety and immunogenicity of a combined intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP). : We conducted a randomized, double-blind, placebo-controlled, phase I trial....
9.
Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models
Banihashemi S, Es-Haghi A, Fallah Mehrabadi M, Nofeli M, Mokarram A, Ranjbar A, et al.
Front Immunol . 2022 Jun; 13:836745. PMID: 35693788
Several vaccine candidates for COVID-19 have been developed, and few vaccines received emergency approval with an acceptable level of efficacy and safety. We herein report the development of the first...
10.
Two Novel Mutations in Gene in Iranian Families Affected by Junctional Epidermolysis Bullosa
Taghdiri M, Naeimi S, Fardaei M, Tabei S
Rep Biochem Mol Biol . 2022 Mar; 10(4):597-601. PMID: 35291611
Background: Junctional epidermolysis bullosa (JEB) is an autosomal recessive skin disorder with defective adhesion of dermal- epidermal within the lamina lucida region of the basement membrane zone. The main characterization...